1. Braun J., Bollow M., Sieper J. Radiology and pathology of the spondyloarthropathies. Rheum Dis Clin North Am.1998; 24: 697-735.

2. Sieper J., Rudwaleit M., Baraliakos X. et al. The Assesment of Spondyloarthritis international Society (ASAS) Handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009; 68 (Suppl. II): ii1-ii44.

3. Folomeeva O.M., Galushko E.A., Erdes Sh.F. Rasprostranennost´ revmaticheskikh zabolevaniy v populyatsiyakh vzroslogo naseleniya Rossii i SShA. Nauchno-prakticheskaya revmatologiya. 2008; 4: 4-13.

4. Braun J., Sieper J. Ankylosing spondylitis. Lancet. 2007; 369 (9570): 1379-90.

5. Van der Linden S., van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am. 1998; 24(4): 663-76.

6. Braun J., Pham T., Sieper J. et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003; 62: 817-24.

7. Vorob´ev P.A. Kliniko-ekonomicheskiy analiz. -Moskva. 2004; S. 10-15.

8. Staquet M.J. Quality of life assessment in clinical trials. Oxford University Press. 1998: 360

9. Amirdzhanova V.N., Koylubaeva G.M. Metodologiya otsenki kachestva zhizni v praktike revmatologa. Nauchno-prakticheskaya revmatologiya. 2003; 2: S. 72-6.

10. Dougados M., Paternotte S., Braun J. et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011; 70: 249-51

11. Braun J., Davis J., Dougados M. et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006; 65: 316-20.

12. Van der Linden S., Valkenburg H., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthr Rheum. 1984; 27: 361-8.

13. Ware J.E., Snow K.K., Kosinski M. et al. SF-36 Health Survey. Manuel and Interpretation Guide. Lincoln, RI: Qualitymetric Inc. 2000; 150.

14. Amirdzhanova V.N., Goryachev D.V., Korshunov N.I., Rebrov A.P., Sorotskaya V.N. Populyatsionnye pokazateli kachestva zhizni po oprosniku SF-36. Nauchno-prakticheskaya revmatologiya. 2008; 1: 37-3.

15. Braun J., Brandt J., Listing A. et al. Two year maintenance of effi cacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. 2005; 64: 229-234.